PriceTargets.com logo

Cullinan Therapeutics - CGEM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $33.86
  • Forecasted Upside: 125.26%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$15.03 As of 10/30/2026 05:00 PM ET
▼ -0.42 (-2.72%)

This chart shows the closing price for CGEM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cullinan Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGEM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGEM

Analyst Price Target is $33.86
▲ +125.26% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Cullinan Therapeutics in the last 3 months. The average price target is $33.86, with a high forecast of $42.00 and a low forecast of $26.00. The average price target represents a 125.26% upside from the last price of $15.03.

This chart shows the closing price for CGEM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 9 polled investment analysts is to moderate buy stock in Cullinan Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/28/2026BTIG ResearchBoost TargetBuy ➝ Buy$40.00 ➝ $41.00
10/19/2026BTIG ResearchReiterated RatingBuy ➝ Buy$40.00
10/2/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/2/2026HC WainwrightReiterated RatingBuy ➝ Buy$35.00
9/25/2026HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $35.00
9/25/2026BTIG ResearchReiterated RatingBuy ➝ Buy$40.00
9/14/2026BTIG ResearchBoost TargetBuy ➝ Buy$39.00 ➝ $40.00
8/24/2026TD CowenUpgradeStrong-Buy
8/17/2026HC WainwrightReiterated RatingBuy ➝ Buy$30.00
8/13/2026WedbushBoost TargetOutperform ➝ Outperform$39.00 ➝ $42.00
7/29/2026BTIG ResearchBoost TargetBuy ➝ Buy$38.00 ➝ $39.00
7/8/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/11/2026WedbushReiterated RatingOutperform ➝ Outperform$37.00
6/8/2026HC WainwrightReiterated RatingBuy ➝ Buy$30.00
5/19/2026BTIG ResearchReiterated RatingBuy ➝ Buy$38.00
5/8/2026WedbushBoost TargetOutperform ➝ Outperform$36.00 ➝ $37.00
5/4/2026BTIG ResearchReiterated RatingBuy ➝ Buy$38.00
4/28/2026BTIG ResearchReiterated RatingBuy ➝ Buy$38.00
4/28/2026HC WainwrightBoost TargetBuy ➝ Buy$27.00 ➝ $30.00
4/10/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/11/2026WedbushBoost TargetOutperform ➝ Outperform$34.00 ➝ $36.00
2/19/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
2/17/2026CitigroupInitiated CoverageBuy$33.00
2/17/2026CitigroupInitiated CoverageBuy$33.00
2/2/2026GuggenheimInitiated CoverageBuy$30.00
2/2/2026GuggenheimInitiated CoverageBuy$30.00
1/21/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
1/8/2026HC WainwrightBoost TargetBuy ➝ Buy$26.00 ➝ $27.00
1/8/2026Morgan StanleyReiterated RatingOverweight ➝ Overweight$30.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/9/2025WedbushBoost TargetOutperform ➝ Outperform$25.00 ➝ $34.00
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025BTIG ResearchBoost TargetBuy ➝ Buy$32.00 ➝ $38.00
11/20/2025New Street ResearchSet Target$26.00
11/20/2025WedbushReiterated RatingOutperform$25.00
11/20/2025HC WainwrightBoost TargetBuy ➝ Buy$24.00 ➝ $26.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/16/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
9/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$24.00
9/10/2025BTIG ResearchReiterated RatingBuy ➝ Buy$32.00
8/21/2025HC WainwrightInitiated CoverageBuy$24.00
8/18/2025Morgan StanleyLower TargetOverweight ➝ Overweight$35.00 ➝ $28.00
6/11/2025Stifel NicolausInitiated CoverageBuy$22.00
5/12/2025UBS GroupLower TargetBuy ➝ Buy$30.00 ➝ $24.00
4/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
3/7/2025Morgan StanleyReiterated RatingOverweight$38.00 ➝ $35.00
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
1/29/2025HC WainwrightBoost TargetBuy ➝ Buy$28.00 ➝ $33.00
10/24/2024UBS GroupInitiated CoverageBuy$30.00
10/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
9/18/2024WedbushReiterated RatingOutperform ➝ Outperform$36.00 ➝ $36.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
8/8/2024WedbushReiterated RatingOutperform ➝ Outperform$36.00 ➝ $36.00
6/3/2024William BlairReiterated RatingOutperform
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/16/2024HC WainwrightLower TargetBuy ➝ Buy$29.00 ➝ $28.00
5/16/2024WedbushReiterated RatingOutperform ➝ Outperform$36.00
5/1/2024Stifel NicolausInitiated CoverageBuy$40.00
4/17/2024JonesTradingBoost TargetBuy ➝ Buy$22.00 ➝ $26.00
4/17/2024BTIG ResearchBoost TargetBuy ➝ Buy$20.00 ➝ $30.00
4/16/2024HC WainwrightLower TargetBuy ➝ Buy$34.00 ➝ $29.00
4/15/2024William BlairInitiated CoverageOutperform
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$34.00
2/15/2024WedbushInitiated CoverageOutperform$30.00
10/6/2023JonesTradingInitiated CoverageBuy$22.00
8/11/2023HC WainwrightLower Target$39.00 ➝ $34.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$49.00
6/15/2023TD CowenInitiated CoverageOutperform
5/12/2023HC WainwrightLower Target$50.00 ➝ $49.00
3/27/2023HC WainwrightReiterated RatingBuy$50.00
3/10/2023HC WainwrightReiterated RatingBuy$50.00
2/15/2023HC WainwrightReiterated RatingBuy$50.00
2/3/2023Morgan StanleyLower TargetOverweight$27.00 ➝ $19.00
11/21/2022BTIG ResearchInitiated CoverageBuy
5/17/2022HC WainwrightReiterated RatingBuy$50.00
3/18/2022HC WainwrightLower TargetBuy$55.00 ➝ $53.00
2/8/2022Leerink PartnersReiterated RatingOutperform
11/15/2021Leerink PartnersReiterated RatingBuy$54.00
(Data available from 10/30/2021 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2026
  • 6 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2026
  • 7 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 7 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Cullinan Therapeutics logo
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $15.03
Low: $14.70
High: $15.72

50 Day Range

MA: $17.91
Low: $12.93
High: $22.95

52 Week Range

Now: $15.03
Low: $6.73
High: $23.19

Volume

389,410 shs

Average Volume

792,188 shs

Market Capitalization

$967.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cullinan Therapeutics?

The following Wall Street sell-side analysts have issued reports on Cullinan Therapeutics in the last year: BTIG Research, Citigroup Inc., Guggenheim, HC Wainwright, Morgan Stanley, New Street Research, TD Cowen, Wall Street Zen, Wedbush, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for CGEM.

What is the current price target for Cullinan Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cullinan Therapeutics in the last year. Their average twelve-month price target is $33.86, suggesting a possible upside of 127.4%. Wedbush has the highest price target set, predicting CGEM will reach $42.00 in the next twelve months. New Street Research has the lowest price target set, forecasting a price of $26.00 for Cullinan Therapeutics in the next year.
View the latest price targets for CGEM.

What is the current consensus analyst rating for Cullinan Therapeutics?

Cullinan Therapeutics currently has 1 sell rating, 1 hold rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CGEM.

What other companies compete with Cullinan Therapeutics?

Other companies that are similar to Cullinan Therapeutics include Tango Therapeutics, CareDx, Xenon Pharmaceuticals, ACADIA Pharmaceuticals and Gemini Therapeutics. Learn More about companies similar to Cullinan Therapeutics.

How do I contact Cullinan Therapeutics' investor relations team?

Cullinan Therapeutics' physical mailing address is One Main Street, Suite 1350, Cambridge, MA, 02142. The company's listed phone number is 617-410-4650 and its investor relations email address is [email protected]. The official website for Cullinan Therapeutics is www.cullinantherapeutics.com. Learn More about contacing Cullinan Therapeutics investor relations.